• Explore /
  • Poster
  • / Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).

Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).

Abstract Poster

Authors

Alexandra Sokolova

Alexandra Sokolova

OHSU Knight Cancer Institute, Portland, OR

Alexandra Sokolova , Julie N. Graff , Claire E Smith , Tomasz M. Beer , Emile Latour , Petros Grivas , Michael Thomas Schweizer , Celestia S. Higano , Joshi J. Alumkal , Jacqueline Vuky , Evan Y. Yu , Heather H. Cheng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT02522715

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5047)

DOI

10.1200/JCO.2023.41.16_suppl.5047

Abstract #

5047

Poster Bd #

141

Abstract Disclosures

Similar Posters

First Author: Constance Thibault

First Author: Antoine Angelergues

First Author: Dana E. Rathkopf

First Author: Johann S. De Bono